- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00015665
Emergency Use of Voriconazole in Patients With Life-Threatening Invasive Fungal Infections
Open-Label, Non-Comparative Protocol for the Emergency Use of Voriconazole in Patients With Life Threatening, Invasive Mycoses Who Are Failing on Currently Available Antifungal Agents
This protocol provides for emergency treatment with the experimental anti-fungal drug voriconazole for patients with life-threatening invasive fungal infections. The increase in the number of patients whose immune function is suppressed because of chemotherapy, tissue or organ transplantation, or HIV infection has led to an increase in fungal infections. New drugs are needed to combat these infections in patients who do not respond to or cannot tolerate standard treatments.
Patients on other primary NIH protocols who have an invasive life-threatening fungal infection that does not respond to currently available treatments or who cannot tolerate these treatments may be eligible for this study.
Participants will have a blood test and a physical examination before receiving voriconazole. They will receive voriconazole twice a day either as an infusion into a vein or as tablets taken by mouth. Adult patients will be asked to provide a blood sample any time after the first dose of voriconazole to be used for developing a test to measure voriconazole concentration in the blood. Patients will be evaluated about 10 days after starting treatment and then at least once every 4 weeks with a symptom check and blood test.
Study Overview
Detailed Description
The increase in the number of immunosuppressed patients as a result of more aggressive chemotherapy, transplantation, HIV infection has lead to an increase in the incidence of invasive fungal infections. Moreover, despite the availability of newer, less toxic preparations of Amphotericin B and azole antifungals such as fluconazole and itraconazole, invasive mycoses remain a therapeutic challenge.
Voriconazole is a new triazole that has shown in phase II studies to be very active against Aspergillus sp. Its side effect profile has been very benign, comparable with those of other FDA approved triazoles. In vitro studies also show that voriconazole has a very broad spectrum ranging from opportunistic to endemic fungi. In addition, the availability of intravenous and oral formulations add to its potential advantages because the therapy of these infections usually require long courses on antifungals.
In this study, voriconazole is used as a salvage therapy for those patients who are unable to tolerate or who have failed other antifungal therapies. Because of the abundance of immunocompromised patients at our center, we believe that having such a protocol ready for enrollment would mitigate delays in such crucial moments. We seek to enroll and treat 40 patients over a 3 year period.
Study Type
Enrollment
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institute of Allergy and Infectious Diseases (NIAID)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
All subjects must have a proven fungal infection that is resistant to standard therapy, or to which the patient is significantly intolerant. (Intolerance must include signs of intolerance such as fever, rigors, laboratory abnormalities, as well as subjective symptoms).
Children are eligible.
EXCLUSION CRITERIA:
AST, ALT greater than 10x the upper limit of normal
Previous hypersensitivity to azole antifungals
Concomitant Rifampin, carbamazepine, or barbiturates or greater than 3 days of such drugs in the 14 days prior to treatment with voriconazole
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Disease Attributes
- Bacterial Infections and Mycoses
- Emergencies
- Mycoses
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Voriconazole
Other Study ID Numbers
- 010150
- 01-I-0150
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mycoses
-
Steven B. KleiboekerNational Institute of Allergy and Infectious Diseases (NIAID)WithdrawnAdenovirus | Other MycosesUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
Fungal Infection Study ForumMerck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Xiamen Amoytop Biotech Co., Ltd.Shanghai Jiao Tong University Affiliated First People's HospitalCompleted
-
Institut National de la Santé Et de la Recherche...UnknownCandidiasisBelgium, France, Italy, Netherlands, Spain
-
PfizerVicuron PharmaceuticalsCompleted
-
Daniel BenjaminEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedFluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams BirthweightCandidiasisUnited States
-
Merck Sharp & Dohme LLCCompleted
Clinical Trials on Voriconazole
-
dingshifangShandong Provincial Hospital; Qianfoshan Hospital; Jinan Military General Hospital and other collaboratorsUnknownInvasive Pulmonary AspergillosisChina
-
PfizerUniversity of Southern CaliforniaCompleted
-
Chong Kun Dang PharmaceuticalCompletedFungal Infections | Candida Infections | Aspergillus InfectionsKorea, Republic of
-
PfizerCompletedCandidemia | CandidiasisUnited States
-
Sara BotrosCompleted
-
Seoul National University HospitalCompletedHealthy VolunteersKorea, Republic of
-
Jan-Willem C AlffenaarUMC Utrecht; Erasmus Medical Center; Amsterdam UMC, location VUmc; Academisch Medisch... and other collaboratorsCompletedInvasive Fungal Infection | Hematological MalignancyNetherlands
-
The Affiliated Hospital of Qingdao UniversityCompleted
-
Zambon SpACompletedAllergic Bronchopulmonary AspergillosisUnited Kingdom
-
Instituto de Investigación Hospital Universitario...UnknownInvasive Fungal InfectionsSpain